Vascular leak ensues a vigorous proinflammatory cytokine response to Tacaribe arenavirus infection in AG129 mice

Virology Journal

Volumn 10, Issue , 2013, Pages

  Sefing, Eric J ^a   Wong, Min Hui ^a   Larson, Deanna P ^a   Hurst, Brett L ^a   Van Wettere, Arnaud J ^a   Schneller, Stewart W ^b   Gowen, Brian B ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Animal model; Arenavirus; Cytokines; Tacaribe virus; Vascular leak

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARENAVIRUS; ARENAVIRUS INFECTION; ARTICLE; BLOOD LEVEL; BLOOD VESSEL PERMEABILITY; BRAIN TISSUE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE COURSE; ENDOLEAK; FEMALE; HEMATOLOGICAL PARAMETERS; INFECTION; KIDNEY PARENCHYMA; LEUKOCYTE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; SPLEEN; SPLENOMEGALY; TISSUE LEVEL; VASCULAR ENDOTHELIUM; VASCULAR LEAK; VIREMIA; VIRUS LOAD; WEIGHT REDUCTION;

ANIMAL STRUCTURES; ANIMALS; ARENAVIRIDAE INFECTIONS; ARENAVIRUSES, NEW WORLD; CAPILLARY PERMEABILITY; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; VIRAL LOAD; VIREMIA;

ANIMALIA; ARENAVIRUS; MUS; NEW WORLD ARENAVIRUSES; TACARIBE VIRUS;

EID: 84879808207     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-221     Document Type: Article

References (20)

1. Nosocomial outbreak of novel arenavirus infection, southern Africa. Paweska JT, Sewlall NH, Ksiazek TG, Blumberg LH, Hale MJ, Lipkin WI, Weyer J, Nichol ST, Rollin PE, McMullan LK, et al. Emerg Infect Dis 2009 15 1598 1602 10.3201/eid1510.090211 19861052
2. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. Delgado S, Erickson BR, Agudo R, Blair PJ, Vallejo E, Albarino CG, Vargas J, Comer JA, Rollin PE, Ksiazek TG, et al. PLoS Pathog 2008 4 1000047 10.1371/journal.ppat.1000047 18421377
3. Pathogenesis of arenavirus hemorrhagic fevers. Moraz ML, Kunz S, Expert Rev Anti Infect Ther 2011 9 49 59 10.1586/eri.10.142 21171877
4. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, Palacios G, Khristova ML, Weyer J, Swanepoel R, Egholm M, et al. PLoS Pathog 2009 5 1000455 10.1371/journal.ppat.1000455 19478873
5. Progress in the experimental therapy of severe arenaviral infections. Gowen BB, Bray M, Future Microbiol 2011 6 1429 1441 10.2217/fmb.11.132 22122440
6. The phylogeny of New World (Tacaribe complex) arenaviruses. Bowen MD, Peters CJ, Nichol ST, Virology 1996 219 285 290 10.1006/viro.1996.0248 8623541
7. Tacaribe virus, a new agent isolated from Artibeus bats and mosquitoes in Trinidad, West Indies. Downs WG, Anderson CR, Spence L, Aitken TH, Greenhall AH, AmJTrop Med Hyg 1963 12 640 646
8. Treatment of Argentine hemorrhagic fever. Enria DA, Briggiler AM, Sanchez Z, Antiviral Res 2008 78 132 139 10.1016/j.antiviral.2007.10.010 18054395
9. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. Rodrigo WW, Ortiz-Riano E, Pythoud C, Kunz S, de la Torre JC, Martinez-Sobrido L, J Virol 2012 86 8185 8197 10.1128/JVI.07240-11 22623788
10. Hemorrhagic fever viruses as biological weapons: medical and public health management. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, et al. JAMA 2002 287 2391 2405 10.1001/jama.287.18.2391 11988060
11. National Institute of Allergy and Infectious Diseases Biodefense Research Agenda for CDC Category A Agents. NIAID, Bethesda, MD: NIAID, NIAID ed, 2006
12. Mice lacking interferon {alpha}/{beta} and {gamma} receptors are susceptible to Junin virus infection. Kolokoltsova OA, Yun NE, Poussard AL, Smith JK, Smith JN, Salazar M, Walker A, Tseng CT, Aronson JF, Paessler S, J Virol 2010 84 13063 13067 10.1128/JVI.01389-10 20926559
13. A STAT-1 knockout mouse model for Machupo virus pathogenesis. Bradfute SB, Stuthman KS, Shurtleff AC, Bavari S, Virol J 2011 8 300 10.1186/1743-422X-8- 300 21672221
14. Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. Gowen BB, Wong MH, Larson D, Ye W, Jung KH, Sefing EJ, Skirpstunas R, Smee DF, Morrey JD, Schneller SW, PLoS One 2010 5 12760 10.1371/journal.pone.0012760 20862280
15. Exotic emerging viral diseases: progress and challenges. Geisbert TW, Jahrling PB, Nat Med 2004 10 110 S121 10.1038/nm1142 15577929
16. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Gowen BB, Julander JG, London NR, Wong MH, Larson D, Morrey JD, Li DY, Bray M, Virol J 2010 7 240 10.1186/1743-422X-7-240 20846417
17. Pathogenesis of viral hemorrhagic fever. Bray M, Curr Opin Immunol 2005 17 399 403 10.1016/j.coi.2005.05.001 15955687
18. Broken barriers: a new take on sepsis pathogenesis. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL, Sci Transl Med 2011 3 88 s25
19. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW, Antimicrob Agents Chemother 2007 51 3168 3176 10.1128/AAC.00356-07 17606691
20. A simple method of estimating fifty percent endpoints. Reed LJ, Muench H, Am J Hyg 1938 27 493 497